DOP2012000012A - Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st - Google Patents

Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st

Info

Publication number
DOP2012000012A
DOP2012000012A DO2012000012A DO2012000012A DOP2012000012A DO P2012000012 A DOP2012000012 A DO P2012000012A DO 2012000012 A DO2012000012 A DO 2012000012A DO 2012000012 A DO2012000012 A DO 2012000012A DO P2012000012 A DOP2012000012 A DO P2012000012A
Authority
DO
Dominican Republic
Prior art keywords
treatment
miocardio
infarto
otamixaban
alteration
Prior art date
Application number
DO2012000012A
Other languages
English (en)
Inventor
Christophe Gaudin
Jens Stechl
Angele Moryusef
Pascale Ythier-Moury
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2012000012A publication Critical patent/DOP2012000012A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencíón se refiere ai uso de éster metíiico dei ácido (2R,3R)-2-(3- carbamimidoii-bencii)-3-[4-(1-oxí-pirídin-4-il)benzoiiamino]-butírico o una sai farmacéuticamente aceptabie dei mismo, para ia preparación de un medicamento para su uso en ei infarto de miocardio sin eievación dei ST, comprendiendo dicho tratamiento administrar una cantidad terapéuticamente eficaz de éster metíiico dei ácido (2R,3R)-2-(3-carbamimidoii-bencii)-3-[4-(1 -oxi-piridin-4-ii)benzoiiamino]- butírico o una sai farmacéuticamente aceptabie dei mismo a un paciente humano, de edad avanzada yío que muestra insuficiencia renai y/o tiene un bajo peso corporai.
DO2012000012A 2009-07-29 2012-01-19 Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st DOP2012000012A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26

Publications (1)

Publication Number Publication Date
DOP2012000012A true DOP2012000012A (es) 2012-02-15

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000012A DOP2012000012A (es) 2009-07-29 2012-01-19 Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st

Country Status (25)

Country Link
US (1) US9492437B2 (es)
EP (1) EP2459193A1 (es)
JP (1) JP2013500298A (es)
KR (1) KR20120038982A (es)
CN (1) CN102470128A (es)
AR (1) AR077427A1 (es)
AU (1) AU2010277725B2 (es)
BR (1) BR112012001900A2 (es)
CA (1) CA2766533A1 (es)
CL (1) CL2012000196A1 (es)
CO (1) CO6491041A2 (es)
CR (1) CR20110674A (es)
DO (1) DOP2012000012A (es)
EC (1) ECSP12011627A (es)
IL (1) IL217612A (es)
MA (1) MA33455B1 (es)
MX (1) MX2012000457A (es)
NI (1) NI201200008A (es)
NZ (1) NZ597957A (es)
PE (1) PE20121401A1 (es)
RU (1) RU2542455C2 (es)
SG (1) SG177772A1 (es)
TW (1) TWI463982B (es)
UY (1) UY32807A (es)
WO (1) WO2011012527A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2597423C2 (ru) * 2011-03-29 2016-09-10 Санофи Бензойнокислая соль отамиксабана
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
CA2883625A1 (en) * 2012-08-31 2014-03-06 Sanofi Otamixaban for use in the treatment of non-st elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273128C (zh) * 1996-01-02 2006-09-06 阿温蒂斯药物公司 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
NZ597957A (en) 2014-05-30
BR112012001900A2 (pt) 2016-03-15
WO2011012527A1 (en) 2011-02-03
KR20120038982A (ko) 2012-04-24
AU2010277725A1 (en) 2012-02-16
IL217612A (en) 2014-08-31
NI201200008A (es) 2012-05-29
CN102470128A (zh) 2012-05-23
TWI463982B (zh) 2014-12-11
CR20110674A (es) 2012-04-17
AR077427A1 (es) 2011-08-24
AU2010277725B2 (en) 2016-08-18
JP2013500298A (ja) 2013-01-07
PE20121401A1 (es) 2012-10-25
US9492437B2 (en) 2016-11-15
MX2012000457A (es) 2012-01-27
SG177772A1 (en) 2012-03-29
RU2542455C2 (ru) 2015-02-20
MA33455B1 (fr) 2012-07-03
EP2459193A1 (en) 2012-06-06
TW201119655A (en) 2011-06-16
UY32807A (es) 2011-02-28
CO6491041A2 (es) 2012-07-31
ECSP12011627A (es) 2012-02-29
CL2012000196A1 (es) 2012-10-05
RU2012107483A (ru) 2013-09-10
US20120238605A1 (en) 2012-09-20
CA2766533A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ702801A (en) Treatment of sanfilippo syndrome type b
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
TR201008226A2 (tr) Kapsül içeren bir inhalasyon cihazı.
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
DOP2012000012A (es) Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
CL2009000919A1 (es) Uso de dronedarona o una sal farmaceuticamente aceptable para preparar un medicamento util en la prevencion y/o tratamiento de la hipocalemia.
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.